Description

Bausch + Lomb’s 500-Basis-Point Margin Leap Signals A Pivotal Reset!

Bausch + Lomb reported a first quarter 2026 marked by solid revenue growth, margin expansion, and ongoing execution of its multi-year strategic plan. Total company revenue reached $1.244 billion, representing 6% year-over-year growth on a constant currency basis, supported by strong performance across its Pharmaceuticals, Vision Care, and Surgical segments. Pharmaceuticals delivered notable momentum with revenue rising 12%, driven primarily by prescription dry eye treatments Miebo and Xiidra, which posted 33% and 30% growth, respectively. This reflects the transition from launch to growth phase, with the company emphasizing a comprehensive dry eye strategy including both prescription and over-the-counter products. Vision Care achieved 5% growth led by contact lenses, especially the daily silicone hydrogel (SiHy) portfolio growing 23%, and consumer eye health products such as LUMIFY and Artelac showing continued strength and geographic expansion.